WIDENING CHASM BETWEEN WHAT CONSUMERS IN HEALTH CARE EXPECT AND WHAT CAN BE DELIVERED
Health Technology Assessment in the United States

Era of Promoting Use of Health Technologies
1946 Hill Burton Act
1965 Regional Medical Program

Beginnings of HTA
Technologies diffused without adequate evaluation of:
Benefits, safety, cost-effectiveness, societal effects

Office of Technology Assessment 1972-94
National Center for Health Care Technology 1978-82

Symposium on Comparative Effectiveness - May 15, 2009
WHAT IS COMPARATIVE EFFECTIVENESS?

RELATIVE BENEFITS OF TREATMENT (ONLY)

• US Institute of Medicine

• US Congressional Budget Office:

ALSO INCLUDES COSTS/COST-EFFECTIVENESS

• Center for Medical Technology Policy

• American College of Physicians

ONLY COSTS/COST-EFFECTIVENESS

• Organization Economic Cooperation and Development
APRIL 10/09: KATHLEEN SEBELIUS ASSURED SENATORS ON THE SENATE FINANCE COMMITTEE THAT COMPARATIVE EFFECTIVENESS RESEARCH WOULD NOT LEAD TO CENTRALIZED COVERAGE DECISIONS, CONSISTENT WITH 2003 MEDICARE MODERNIZATION ACT.

SHE EMPHASIZED THE GOAL OF ANY GOVERNMENT-LED COMPARATIVE EFFECTIVENESS RESEARCH WOULD BE TO: ``PROVIDE ADDITIONAL INFORMATION TO PATIENTS AND PROVIDERS TO HELP THEM MAKE THE BEST DECISIONS POSSIBLE REGARDING TREATMENT OPTIONS.``
WHO GETS COVERED?

- Ron Akehurst
- Egon Jonsson

FOR WHOM?

- Mark Sculpher
- Andrew Briggs

IS THE BENEFIT WORTH THE COST?

- Kathy Buto - Mark Helfand

MODERATING THE SESSIONS

- Lou Garrison
- Seema Sonnad
### WELCOME & OVERVIEW

**Moderator:** Adrian Levy PhD, Associate Professor, University of British Columbia & Director, Oxford Outcomes, Vancouver, BC, Canada

### COMPARATIVE EFFECTIVENESS IN THE UK

**Ron Akehurst Hon MFPHM,** Professor of Health Economics. Dean School of Health and Related Research, University of Sheffield

### COMPARATIVE EFFECTIVENESS IN SWEDEN

**Egon Jonsson PhD,** Executive Director and CEO, Institute of Health Economics, Alberta, Canada

### COVERAGE WITH EVIDENCE DEVELOPMENT: THE ONTARIO EXPERIENCE

**Ron Goeree BA, MA,** Associate Professor, Department of Clinical Epidemiology & Biostatistics, McMaster University

### COMPARATIVE ASSESSMENT FOR MEDICATIONS AND DEVICES: APPLES AND ORANGES?

**Scott Ramsey MD, PhD,** Professor, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

### CONTEMPORARY CHALLENGES IN DERIVING ESTIMATES OF COMPARATIVE EFFECTIVENESS USING META-ANALYSIS

**Ed Mills MSc, PhD, LLM,** Research Scientist, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

### NETWORK META-ANALYSIS: THE NEXT STEP FOR COMPARATIVE EFFECTIVENESS?

**Neil Hawkins PhD, MSc,** Director, Oxford Outcomes, External Affiliate, York University, York, UK

### REFLECTING HETEROGENEITY IN PATIENT BENEFITS: THE ROLE OF SUB-GROUP ANALYSIS WITH COMPARATIVE EFFECTIVENESS

**Mark Sculpher PhD** Professor of Health Economics University of York, Centre for Health Economics, York, UK

### TRANSPORTABILITY BETWEEN COUNTRIES OF ESTIMATES OF COMPARATIVE EFFECTIVENESS

**Andrew Briggs BA, MSc, DPhil,** Lindsay Chair in Health Policy and Economic Evaluation, University of Glasgow, Scotland

### EXPERIMENTAL AND OBSERVATIONAL DATA AND FORMULARY LISTING

**Raulo Frear Pharm.D,** Director, Pharmacy Services, Regence / RegenceRx, Idaho USA

### NET CLINICAL BENEFIT: THE ART AND SCIENCE OF JOINTLY ESTIMATING BENEFITS AND RISKS OF TREATMENT

**Adrian Towse MA, MPhil,** Director, Office of Health Economics, London, UK

### LESSONS FOR THE USA - Lou Garrison AB, PhD,

**Pro:** Kathy Buto BA, MPA, Vice President for Health Policy, Government Affairs, Johnson & Johnson, NJ, USA

**Con:** Mark Helfand MD, MPH, Director, Oregon Evidence-based Practice Center, Portland, Oregon, USA

### DEBATE: PUBLICLY FUNDED ESTIMATES OF COMPARATIVE VALUE IN THE UNITED STATES SHOULD TAKE INTO CONSIDERATION ONLY NET CLINICAL BENEFIT AND EXPLICITLY EXCLUDE COST-EFFECTIVENESS

**Moderator:** Seema Sonnad PhD, Director of Outcomes Research for the Department of Surgery, Pennsylvania Health System
Proposition: Conducting cost effectiveness analyses should not be included in the mandate of a US federal agency carrying out comparative effectiveness research

**Moderator:** Seema Sonnad PhD, Director of Outcomes Research for the Department of Surgery, Pennsylvania Health System

**Pro:** Kathy Buto BA, MPA, Vice President for Health Policy, Government Affairs, Johnson & Johnson, NJ, USA

**Con:** Mark Helfand MD, MPH, Director, Oregon Evidence-based Practice Center, Portland, Oregon, USA